First Time Loading...
C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91% Market Closed
Updated: Jun 16, 2024
Have any thoughts about
Cellivery Therapeutics Inc?
Write Note

Intrinsic Value

Cellivery Therapeutics Inc's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. [ Read More ]

The intrinsic value of one Cellivery Therapeutics Inc stock under the Base Case scenario is 1 400.36 KRW. Compared to the current market price of 6 680 KRW, Cellivery Therapeutics Inc is Overvalued by 79%.

Key Points:
Intrinsic Value
Base Case
1 400.36 KRW
Overvaluation 79%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
Cellivery Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Cellivery Therapeutics Inc stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cellivery Therapeutics Inc

Current Assets 5.7B
Cash & Short-Term Investments 589.8m
Receivables 1.8B
Other Current Assets 3.3B
Non-Current Assets 20.2B
Long-Term Investments 1.1B
PP&E 17.8B
Intangibles 438.8m
Other Non-Current Assets 957.6m
Current Liabilities 53.9B
Accounts Payable 2.9B
Accrued Liabilities 6.5B
Short-Term Debt 16.1B
Other Current Liabilities 28.4B
Non-Current Liabilities -725.6m
Long-Term Debt 368.7m
Other Non-Current Liabilities -1.1B
Efficiency

Earnings Waterfall
Cellivery Therapeutics Inc

Revenue
22B KRW
Cost of Revenue
-22B KRW
Gross Profit
3.9m KRW
Operating Expenses
-21.8B KRW
Operating Income
-21.7B KRW
Other Expenses
-13.6B KRW
Net Income
-35.3B KRW

Free Cash Flow Analysis
Cellivery Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Cellivery Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional ROE
ROE is Increasing
ROIC is Increasing
32/100
Profitability
Score

Cellivery Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Positive Net Debt
Short-Term Solvency
18/100
Solvency
Score

Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Cellivery Therapeutics Inc

There are no price targets for Cellivery Therapeutics Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Cellivery Therapeutics Inc

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
-86%
5Y 5Y
-46%
10Y 10Y
-7%
Annual Price Range
6 680
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return 60.58%
Standard Deviation of Annual Returns 135.87%
Max Drawdown -93%
Shares Statistics
Market Capitalization 244.9B KRW
Shares Outstanding 36 670 000
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cellivery Therapeutics Inc

Country

Korea

Industry

Life Sciences Tools & Services

Market Cap

244.9B KRW

Dividend Yield

0%

Description

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Contact

SEOUL
Seoul
9F, K-BIZ DMC Tower, 189, Seongam-ro, Mapo-gu
+82231518900
http://www.cellivery.com/

IPO

2018-11-09

Employees

87

Officers

See Also

Discover More
What is the Intrinsic Value of one Cellivery Therapeutics Inc stock?

The intrinsic value of one Cellivery Therapeutics Inc stock under the Base Case scenario is 1 400.36 KRW.

Is Cellivery Therapeutics Inc stock undervalued or overvalued?

Compared to the current market price of 6 680 KRW, Cellivery Therapeutics Inc is Overvalued by 79%.